Venkat Jasti, Chairman & CEO, Suven Life Sciences, speaks on the firm's Q4FY23 results and Suven Neuro's listing plans. Listen in.

#suvenlifesciences #Q4FY23earnings #Q4FY23revenue #cnbctv18 #businessnews #businessnewstoday #businessnewsinenglish #sharemarkettoday   

About CNBC-TV18: India's leading business news channel, CNBC-TV18 offers the most comprehensive coverage of businesses, the economy and the financial markets. Catch all your favourite shows, exclusive videos, big-ticket interviews and more here. 

You can also connect with CNBC-TV18 News Online
Catch the latest news: https://bit.ly/2YbpXBM

Follow CNBC-TV18 round the clock: https://www.cnbctv18.com/live-tv/

Stay updated with all the market action in real time: https://www.cnbctv18.com/market-live/

You can also stay updated with all the latest news on-the-go with CNBC-TV18 Minis: https://www.cnbctv18.com/minis/

n18oc_business

About CNBC-TV18: India's leading business news channel, CNBC-TV18 offers the most comprehensive coverage of businesses, the economy and the financial markets. Catch all your favourite shows, exclusive videos, big-ticket interviews and more here. 
You can also connect with CNBC-TV18 News Online
Catch the latest news: https://bit.ly/2YbpXBM

Follow CNBC-TV18 round the clock: https://www.cnbctv18.com/live-tv/

Stay updated with all the market action in real time: https://www.cnbctv18.com/market-live/

You can also stay updated with all the latest news on-the-go with CNBC-TV18 Minis: https://www.cnbctv18.com/minis/

Subscribe to our Channel: https://bit.ly/3nvEcxf

Like us on Facebook: https://www.facebook.com/cnbctv18india/
Follow us on Twitter: https://twitter.com/CNBCTV18News
Follow us on Instagram: https://www.instagram.com/cnbctv18india/
Catch us on: Linkedin: https://in.linkedin.com/company/cnbc-tv18
n18oc_business

Suven Life Sciences' Venkat Jasti Speaks On Weak Q4 Results & Suven Neuro Listing Plans | CNBC-TV18

Q4 Review | Suven Life Sciences’ Q4 Report Card & FY24 Projections #Q4WithBQ | Suven Life Sciences’ revenue contracts and loss widens on an yearly basis. Can company see improved performance in FY24?In conversation with Chairman & CEO Venkat Jasti.

Q4 Review | Suven Life Sciences’ Q4 Report Card & FY24 Projections

Suven Life Sciences' revenue contracts and loss widens on a yearly basis. Can company see improved performance in FY24? 

In conversation with Chairman & CEO Venkat Jasti. #Q4WithBQ #BQLive 

--------------------------------------------------------------------------------------------------------------------
For more videos subscribe to our channel: http://bit.ly/32JXa74
Visit BQ Prime for more news: https://www.bqprime.com/
Don't enter the stock market unaware. Read all Research Reports here: https://www.bqprime.com/research-reports
For the latest business news and analysis
Subscribe to our Newsletters here: https://www.bqprime.com/my-bq/newsletter
Subscribe to our Telegram channel: https://t.me/BQPrime
Follow BQ Prime here
Twitter: https://twitter.com/bqprime
Facebook: https://www.facebook.com/BQPrime/
LinkedIn: https://www.linkedin.com/company/13184554/
Instagram: https://www.instagram.com/bqprime/
Pinterest: https://in.pinterest.com/BQPrimeNews/

Q4 Review | Suven Life Sciences’ Q4 Report Card & FY24 Projections | BQ Prime

The funding to keep his drug discovery pursuits alive may not be a problem, as Jasti in December last year sold his profitable contract development and manufacturing services (CDMO) venture Suven Pharmaceuticals to private equity firm Advent International for ₹6,313 crore.

Suven Life Sciences breathes new life into drug discovery plans

RIL-promoted Alok Industries, Bombay Dyeing and Manufacturing Co, Wockhardt, Suven Life Sciences, Spencers Retail, Inox Wind, Sagar Cements, Restaurant Brands, Religare Enterprises, and Orissa Mineral Development Co, among others also remained in the red for 4 straight quarters.

RIL-backed co, new-age techies among 41 firms to post losses for 4 straight quarters

Promoters Venkateswarlu Jasti and his family split Suven Life Sciences in FY20, turning the CRAMS business into a separately listed company via a demerger. The promoters own 60% of the company, which has a market value of ₹12,278.94 crore, based on the Thursday close.

Advent closes in on Suven Pharma buyout

We zoom in on the prospects of Tech Mahindra, as also that of two other stocks — TTK Prestige and Suven Life Sciences

Tech Query: Is the trend in Tech Mahindra reversing?

Suven Life Sciences’ record date for rights issue has been fixed on 18th October 2022

Suven Life Science rights issue: Record date announced. 5 things you should know

Suven Life Sciences rose 2.19% to Rs 72.30 after the company said its board approved the terms of its upcoming rights issue.

Suven Life gains after unveiling terms of rights issue

The company said the board of directors has approved rights issue size of 7,26,91,239 shares for Rs399.80 crore.

Suven Life Sciences gains 4% on receiving approval to raise Rs400 crore via rights issue

Suven Life Sciences Ltd is a small-cap company with a market capitalization of ₹1,028.58 crore that operates in the pharmaceutical industry

Multibagger stock surges 606% in 5 years, fixes record date for 1:2 rights issue

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Profitability and efficiency haven't been upto the mark

Profitability

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Suven Life Sciences Limited is a bio-pharmaceutical company, engaged in the business of manufacture and sale of bulk drugs and intermediaries.